Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node–Positive Prostate Cancer and Mortality Risk
European Urology Focus · 2026-10 · 12 (5) · 948-955
DOI: 10.1016/j.euf.2026.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Mutlay Sayan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA. Electronic address: msayan@bwh.harv…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lymph Nodes, Lymphatic Irradiation. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Whether including pelvic lymph nodes in postradical prostatectomy (RP) radiotherapy (RT) volume for patients with pathologically node-positive (pN1) prostate cancer (PC) is associated with differences in mortality remains uncertain. METHODS: Multivariable Cox and Fine-Gray regression analyses were performed to evaluate whether use of whole-pelvic lymph node RT (WPRT) plus prostate bed RT (PBRT), compared with PBRT alone, was associated with all-cause mortality (ACM) and PC-specific mortality (PCSM) in this retrospective single-institution cohort of 816 patients with pT2-4pN1M0 PC treated with RP after adjusting for age at and year of RT delivery, pre-RT prostate-specific antigen level, pGleason score, pTumor stage, surgical margin status, number of removed and positive pelvic lymph nodes, and time-dependent use of androgen deprivation therapy. Covariate-adjusted estimates of ACM were generated using the extended Kaplan-Meier method. KEY FINDINGS AND LIMITATIONS: After a median follow-up of 4.83 yr (interquartile range: 3.84-5.90), the addition of WPRT to the postoperative RT treatment volume was associated with a significantly reduced ACM risk (adjusted hazard ratio [AHR], 0.30; 95% confidence interval [CI], 0.17-0.52; p < .001) and PCSM-risk (AHR, 0.42; 95% CI, 0.19-0.91; p = .03) compared with PBRT alone. Key limitations include the retrospective single-institution design, evolving systemic therapies, and limited PSMA positron emission tomography imaging. CONCLUSION AND CLINICAL IMPLICATIONS: WPRT was associated with lower risks of ACM and PCSM among patients receiving postoperative RT for pN1 PC. These findings warrant further investigation in appropriately designed prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA. Electronic address: msayan@bwh.harvard.edu.
- Department of Statistics, Ankara University, Ankara, Türkiye.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospi…
Zitieren
APA
Sayan, M., Tuac, Y., Graefen, M., D'Amico, A. V., & Tilki, D. (2026). Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node–Positive Prostate Cancer and Mortality Risk. European Urology Focus, 12(5), 948-955. https://doi.org/10.1016/j.euf.2026.06.008
Vancouver
Sayan M, Tuac Y, Graefen M, D'Amico AV, Tilki D. Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node–Positive Prostate Cancer and Mortality Risk. European Urology Focus. 2026;12(5):948-955. doi:10.1016/j.euf.2026.06.008
BibTeX
@article{Sayan2026,
author = {Sayan, Mutlay and Tuac, Yetkin and Graefen, Markus and D'Amico, Anthony V and Tilki, Derya},
title = {Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node–Positive Prostate Cancer and Mortality Risk},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {948--955},
doi = {10.1016/j.euf.2026.06.008}
}
EUVIMED